19:52 , Dec 22, 2017 |  BC Week In Review  |  Clinical News

Stemline reports additional Phase II data for SL-701 in GBM

In November, Stemline Therapeutics Inc. (NASDAQ:STML) reported additional data from the two-stage Phase II STML-701-0114 trial of SL-701 as a second-line treatment of glioblastoma multiforme (GBM). Data were presented at the Society of Neuro-Oncology...
23:20 , Dec 14, 2017 |  BC Innovations  |  Product R&D

Opening doors in PML

An NIH-led team has demonstrated that neutralizing antibodies can prevent infection of cells by mutant strains of JCV -- the virus responsible for the lethal brain infection PML. In a field with no clinical options,...
21:34 , Jan 6, 2017 |  BC Week In Review  |  Clinical News

SL-701: Preliminary Ph II STML-701-0114 data

Preliminary data from 42 evaluable patients with relapsed or refractory GBM in stage 1 of the 2-stage, open-label, U.S. Phase II STML-701-0114 trial showed that second-line treatment with subcutaneous SL-701 plus GM-CSF and imiquimod led...
23:04 , Jan 3, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cancer Mouse studies suggest a photo-activated imiquimod-loaded nanoparticle could help treat cancer. The nanoparticle consisted of poly(lactic-co-glycolic) acid (PLGA) loaded with indocyanine green, a dye that generates tumor cell-killing heat when exposed to near-infrared (NIR)...
07:00 , Jul 18, 2016 |  BC Week In Review  |  Clinical News

ProCervix: Additional Phase II data

Additional data from 233 evaluable patients ages 25-50 infected with HPV types 16 and/or 18 in the double-blind, European Phase II RHEIA-VAC trial showed that 2 intradermal vaccinations of 600 ug GTL001 given 6 weeks...
08:00 , Mar 7, 2016 |  BC Week In Review  |  Clinical News

HTERT peptide vaccine: Phase I started

The partners began the open-label, U.K. Phase I VAPER trial to evaluate intradermal hTERT peptide vaccine given every 3 weeks in up to 30 patients. All patients will receive imiquimod and cyclophosphamide, and half of...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Clinical News

ProCervix: Phase II data

Top-line data from 232 evaluable patients ages 25-50 infected with HPV types 16 and/or 18 in the double-blind, European Phase II RHEIA-VAC trial showed that 2 intradermal vaccinations of GTL001 given 6 weeks apart plus...
02:24 , Jan 28, 2016 |  BC Extra  |  Clinical News

Genticel's ProCervix misses HPV endpoint

Genticel S.A. (Euronext:GTCL) said ProCervix ( GTL001) missed the primary endpoint in the European Phase II RHEIA-VAC trial, which evaluated the potential of the bivalent therapeutic vaccine to prevent cervical cancer by enhancing immune response...
08:00 , Nov 16, 2015 |  BC Week In Review  |  Clinical News

ProCervix: Phase I started

Genticel began an open-label, U.S. Phase I trial to evaluate 2 intradermal vaccinations of 600 ug GTL001 given 6 weeks apart in 20 patients ages 25-65 infected with HPV types 16 and/or 18. Patients receive...
07:00 , Oct 20, 2014 |  BioCentury  |  Product Development

Walking the toll road

Even after a series of clinical setbacks in the mid-2000s cooled investor and pharma interest in the once white-hot field of toll-like receptors, several companies continued toiling away. Now the spark may be rekindling as...